| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP3A7 |
| Uniprot No | P24462 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-503aa |
| 氨基酸序列 | MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTFDMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISIAEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYSMDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITVFPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSIIFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVVNETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFGGLLLTEKPIVLKAESRDETVSGA |
| 预测分子量 | 64.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CYP3A7重组蛋白的3篇参考文献概述，基于模拟数据整理：
---
1. **标题**: "Functional expression and characterization of recombinant human CYP3A7 in Escherichia coli: Role in fetal drug metabolism"
**作者**: Smith J, et al.
**摘要**: 本研究成功在大肠杆菌中表达了重组CYP3A7蛋白，并对其酶动力学特性进行了分析。结果表明，CYP3A7对特定内源性类固醇(如脱氢表雄酮)具有高代谢活性，提示其在胎儿发育阶段的生理作用可能优于药物代谢。
2. **标题**: "Comparative analysis of CYP3A7 and CYP3A4 recombinant enzymes in insect cell systems"
**作者**: Tanaka K, et al.
**摘要**: 通过在昆虫细胞(Sf9)中重组表达CYP3A7和CYP3A4.比较了两者的底物特异性和代谢效率。研究发现，CYP3A7对部分药物的亲和力显著低于CYP3A4.但在孕烷X受体(PXR)介导的调控机制中表现出独特响应。
3. **标题**: "Structural insights into CYP3A7 through recombinant protein crystallography"
**作者**: Müller R, et al.
**摘要**: 利用重组CYP3A7蛋白成功解析其晶体结构，揭示了与CYP3A4相比的关键氨基酸差异。这些结构差异可能解释CYP3A7在底物结合口袋的独特构象及其在胎儿期特异性表达的功能基础。
---
**备注**：以上文献信息为模拟生成，实际引用时需通过PubMed或Web of Science等平台核实具体文献内容及作者信息。
CYP3A7 is a member of the cytochrome P450 (CYP) superfamily of enzymes, which play critical roles in the metabolism of endogenous compounds and xenobiotics, including drugs, toxins, and steroids. Primarily expressed in the fetal liver, CYP3A7 is one of the dominant CYP isoforms during embryonic and early postnatal development. Its expression declines shortly after birth, replaced by CYP3A4. the major drug-metabolizing enzyme in adults. CYP3A7 is involved in the oxidation of endogenous substrates such as dehydroepiandrosterone (DHEA) and estrogens, contributing to steroid homeostasis during fetal growth. It also metabolizes certain pharmaceuticals, though its substrate specificity and catalytic efficiency differ from CYP3A4.
Recombinant CYP3A7 protein is produced using heterologous expression systems (e.g., Escherichia coli, yeast, or mammalian cells) to study its enzymatic properties, structure-function relationships, and interactions with drugs or inhibitors. This engineered protein allows researchers to bypass the ethical and practical challenges of obtaining fetal tissue samples. Studies using recombinant CYP3A7 have revealed unique catalytic behaviors, such as altered regioselectivity or reduced activity toward specific substrates compared to CYP3A4. These differences are attributed to structural variations in substrate-binding regions, including amino acid substitutions in helices and β-sheets that influence ligand access and binding.
Research on recombinant CYP3A7 has implications for understanding fetal pharmacology, as its activity may affect drug exposure and toxicity during pregnancy. Additionally, CYP3A7 polymorphisms or aberrant expression in adults have been linked to diseases like childhood cancers or hormone-related disorders. Despite advances, challenges remain in fully characterizing its physiological roles and extrapolating in vitro findings to in vivo contexts. Ongoing work aims to refine expression systems for higher yields and improved stability, enabling deeper mechanistic insights and applications in drug development or personalized medicine.
×
